In 2017, we announced an investment of over £4.5 million into five new transformational commitments, to provide everyone living with a muscle-wasting condition with choices – to live a life unlimited, understood and never alone.
We believe our five-year investments will make a profound impact on lives, from the moment of diagnosis, improving quality of life, while also seeking to extend them.
These game-changing commitments are designed to increase the number of clinical trials taking place in the UK and to improve the overall care and support for all people living with a muscle-wasting condition.
The biggest challenges in our field require multi-partner approaches to change the landscape. By working in partnership with world-renowned organisations we can share expertise to accelerate the path to treatments and improve clinical care.
Together, we can beat muscle-wasting conditions through accelerating research, driving access to the best of healthcare and enabling independence. Because everyone has the right to live their life to the fullest.
Tickets are £125 per household and include three bottles of wine
Find out about the research updates shared at the meeting
SMA gene treatment Zolgensma accepted for restricted use
Add your voice to our biggest consultation yet